Psycho-social Intervention With Paro Robotic Seal Focused on Patients With Dementia

Overview

The overall objective of the study is to evaluate the improvement in patient-perceived quality of life following the use of the Paro robot integrated with traditional intervention in the elderly with dementia.

Full Title of Study: “PARO: Psycho-social Intervention With Paro Robotic Seal Focused on Patients With Dementia”

Study Type

• Study Type: Interventional
• Study Design
  • Allocation: Randomized
  • Intervention Model: Parallel Assignment
  • Primary Purpose: Other
  • Masking: Single (Outcomes Assessor)
• Study Primary Completion Date: April 29, 2023

Detailed Description

The primary aim of this study is to evaluate the patient-perceived improvement in terms of quality of life through Quality of Life – Alzheimer's Disease (QoL-AD), following the use of the Paro robot, integrated with traditional intervention carried out within the IRCCS INRCA Alzheimer's Day Center. The Secondary aims are the evaluation of the improvement in cognitive status of the elderly person with dementia, in terms of orientation, attentional-executive, mnestic and visuospatial functions, detected through the Addenbrooke's Cognitive Examination (ACE-R); the assessment of mood improvement in terms of reduction of anxiety and depression, detected through the Rating Anxiety In Dementia (RAID) scale and the Cornell Scale for Depression in Dementia (CSDD); the assessment of the elderly person's acceptance of the technology through Quebec User Evaluation of Satisfaction (QUEST 2.0), semi-structured interview and analysis of physiological activation during interaction, with the Noldus Face Reader system and direct observation by the operator; the analysis of behavioral symptomatology through Neuropsychiatric Inventory (NPI); the assessment of practitioner's acceptance of technology through Technology Acceptance Model (TAM) and the assessment of job quality through semi-structured interview.

Interventions

• Device: PARO robot
  • PARO is an advanced interactive robot. It allows the documented benefits of animal therapy to be administered to patients in environments such as hospitals and extended care facilities where live animals present treatment or logistical difficulties. PARO has five kinds of sensors: tactile, light, audition, temperature, and posture sensors, with which it can perceive people and its environment. PARO can learn to behave in a way that the user prefers, and to respond to its new name.

Arms, Groups and Cohorts

• Experimental: Experimental Group
  • The Experimental Group will receive for 12 weeks a robotic training with Paro robot combined with traditional training.
• No Intervention: Control Group
  • The Control Group will receive only the traditional therapy.

Clinical Trial Outcome Measures

Primary Measures

• changes in quality of life
  • Time Frame: baseline, 12 and 24 weeks later
  • This outcome will be assesed by the Quality of life in Alzheimer’s Disease (QoL-AD) test. The QoL-AD is comprised of 13 items (physical health, energy, mood, living situation, memory, family, marriage, friends, self as a whole, ability to do chores, ability to do things for fun, money and life as a whole). Response options include 1(poor), 2(fair), 3(good) and 4 (excellent), for a total score of 13-52, with higher scores indicating better QoL.

Secondary Measures

• changes in cognitive status
  • Time Frame: baseline, 12 and 24 weeks later
  • This outcome will be assessed by the Addenbrooke’s Cognitive Examination (ACE-R). It contains5 sub-scores, each one representing one cognitivedomain: attention/orientation (18 points), memory(26 points), fluency (14 points), language (26 points)and visuospatial (16 points). ACE-R maximum score is 100, composed by the addition of the all domains. is scored out of 100, with a higher score denoting better cognitive function.
• changes in mood
  • Time Frame: baseline, 12 and 24 weeks later
  • This outcome will be assessed by the Rating Anxiety In Dementia (RAID). Rating should be based on symptoms and signs occurring during two weeks prior to the interview. No score should be given if symptoms result from physical disability or illness. Total score is the sum of items 1 to 18. A score of 11 or more suggests significant clinical anxiety.
• changes in signs and symptoms of major depression
  • Time Frame: baseline, 12 and 24 weeks later
  • This outcome will be assessed by the Cornell Scale for Depression in Dementia (CSDD). Information is elicited through two semi-structured interviews: an interview of an informant and an interview of the patient. Each item is rated for severity on a scale of 0-2 (0=absent, 1=mild or intermittent, 2=severe). The item scores are added. Scores above 10 indicate a probable major depression. Scores above 18 indicate a definite major depression. Scores below 6 as a rule are associated with absence of significant depressive symptoms.
• changes in acceptance of the technology
  • Time Frame: baseline, 12 and 24 weeks later
  • This outcome will be assessed by the technology through Quebec User Evaluation of Satisfaction (QUEST 2.0). The QUEST 2.0 evaluates the patient’s satisfaction with various assistive technologies.

Participating in This Clinical Trial

Inclusion Criteria

• Diagnosis of mild-moderate dementia according to the Diagnostic and Statistical Manual of Mental Disorders (DSM V). – MMSE between 10 and 24 – Attending the Alzheimer's Day Center since at least 3 months – Presence of a caregiver Exclusion Criteria:

• Severe sensory disabilities (visual and auditory) – Comprehension difficulties – History of syncopal episodes, epilepsy, and dizziness not controlled pharmacologically – Severe autonomic system dysfunction – Severe behavioral syndromes not compensated by medication

Gender Eligibility: All

Minimum Age: 65 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

• Lead Sponsor
  • Istituto Nazionale di Ricovero e Cura per Anziani
• Provider of Information About this Clinical Study
  • Sponsor
• Overall Official(s)
  • Roberta Bevilacqua, Principal Investigator, IRCCS INRCA
• Overall Contact(s)
  • Anna Rita Bonfigli, 00390718003719, a.bonfigli@inrca.it